Latest from the FHSC registry: take action now for universal cholesterol screening in early life

Commentary to publication: Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. The Lancet; Familial hypercholesterolaemia (FH) is the most common inherited lipid disorder, affecting about one in 300 people worldwide (1). If untreated, elevated low-density lipoprotein cholesterol (LDL‑C) levels from birth confer an increased risk of premature atherosclerotic cardiovascular disease. … Read more

Global FHSC registry makes the case for universal cholesterol screening of children for familial hypercholesterolaemia

December 13, 2023 – Gothenburg, Sweden Finding children with familial hypercholesterolaemia (FH), the most common inherited lipid disorder, relies on family cascade screening, usually after a parent or relative has a heart attack, as physical signs of FH in children are uncommon, meaning that detection is delayed in most. These were the key findings from … Read more

Consensus on Familial Hypercholesterolaemia in Children and Adolescents

Familial Hypercholesterolaemia in children and adolescents: gaining decades of life by optimising detection and treatment Consensus Statement of the European Atherosclerosis Society Publication in full Featured Commentary Slide set Authors Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche … Read more

Consensus on FH

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease Consensus Statement of the European Atherosclerosis Society Publication in full Slide set Featured Commentary Authors Børge G. Nordestgaard*, M. John Chapman*, Steve E. Humphries, Henry N. Ginsberg, Luis Masana, Olivier S. Descamps, Olov Wiklund, Robert A. Hegele, … Read more

Guidelines on management of dyslipidaemia 2016

These updated 2016 guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. The guidance includes sections on: the evaluation of laboratory lipid and apolipoprotein parameters; treatment targets; lifestyle modifications to improve the plasma lipid profile; drugs for treatment of hypercholesterolaemia and hypertriglyceridaemia; drugs affecting HDL-cholesterol; managing dyslipidaemias in different … Read more


European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk A joint consensus statement from the European Society of Cardiology and the European Atherosclerosis Society Task Force. Publication in full Authors Ulf Landmesser, M. John Chapman, Michel … Read more

Homozygous familial hypercholesterolaemia: new hope for getting patients to goal?

Management of homozygous familial hypercholesterolaemia is challenging. What are the prospects for attaining LDL cholesterol goal with novel therapies? This latest commentary discusses the new findings for evinacumab, an ANGPTL3 monoclonal antibody. The European Atherosclerosis Society (EAS) continues to be a key player in familial hypercholesterolaemia (FH), raising awareness and supporting research to promote early … Read more

HICC registry: levelling up access to treatment urgently needed

Commentary to publication: Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. The Lancet; Familial hypercholesterolaemia (FH) is an inherited condition characterised by markedly elevated low-density lipoprotein cholesterol (LDL-C) levels from birth, which if undiagnosed and untreated, confer an increased risk of premature atherosclerotic cardiovascular disease. The most severe presentation is homozygous FH, estimated … Read more

FHSC new publication in The Lancet – highlighting the challenges of FH

September 07, 2021 – Gothenburg, Sweden First data from the European Atherosclerosis Society (EAS) Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry of over 42,000 individuals from 56 countries, provides a unique snapshot into the worldwide burden and challenges of FH care. Detection needs to be earlier, with greater use of intensive lipid-lowering therapy, including combination … Read more

Improving FH care: first survey data from EAS FHSC

2019-04-26 Five years ago, the European Atherosclerosis Society (EAS) was a trailblazer in highlighting the underdiagnosis and undertreatment of familial hypercholesterolaemia (FH, inherited high cholesterol) in a Consensus Panel initiative.1 This was followed by subsequent statements, specifically focusing on homozygous FH,2 and importantly, FH in children and adolescents.3 Supported by other international evidence,4-7 the EAS recognised the worldwide lack … Read more